We are live on ! Find out more
NWBO

Northwest Biotherapeutics, Inc. Common stock
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

Back to rankings

9 hedge funds and large institutions have $175K invested in Northwest Biotherapeutics, Inc. Common stock in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

1% more capital invested

Capital invested by funds: $174K → $175K (+$1.64K)

0% more funds holding

Funds holding: 9 → 9 (0)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
9
Holders Change
–
Holders Change %
0%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MSAM
Moloney Securities Asset Management
Missouri
+$7.96K

Top Sellers

Rank Fund Capital Flow
1
EFG
Ethos Financial Group
Pennsylvania
-$5.69K
Name Holding Trade Value Shares
Change 		Change in
Stake
MSAM
1
Moloney Securities Asset Management
Missouri
$128K +$7.96K +33,150 +7%
VWA
2
VSM Wealth Advisory
Maryland
$15.8K – – –
OCG
3
Opus Capital Group
Ohio
$14K – – –
WJWM
4
Williams Jones Wealth Management
New York
$6.49K – – –
EFG
5
Ethos Financial Group
Pennsylvania
$6.09K -$5.69K -23,700 -48%
KA
6
KLCM Advisors
Wisconsin
$2.4K – – –
AMG
7
Advisors Management Group
Wisconsin
$2K – – –

NWBO Hedge Fund Activity: Q3 2025 in Review

9 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q3 2025, worth a combined $175K — up 0.95% from $174K a quarter earlier.

Fund positioning in NWBO was balanced in Q3 2025: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Moloney Securities Asset Management, adding an estimated $7.96K. The largest seller was Ethos Financial Group, cutting an estimated $5.69K.

  • 9 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q3 2025, unchanged from Q2 2025.
  • Funds reported $175K of Northwest Biotherapeutics, Inc. Common stock stock for Q3 2025, up 0.95% quarter-over-quarter.
  • 0 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q3 2025 and 0 closed out.
  • The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q3 2025 was Moloney Securities Asset Management, an estimated $7.96K added.
  • The largest Northwest Biotherapeutics, Inc. Common stock seller in Q3 2025 was Ethos Financial Group, an estimated $5.69K sold.

Based on aggregated 13F filings for Q3 2025.